Acyclic Carbon Chain Containing Carbon To Carbon Unsaturation Attached Directly Or Indirectly To The Lactone Ring By Nonionic Bonding Patents (Class 549/312)
  • Patent number: 9212976
    Abstract: A method for removing supernatant from a sample tube. The method includes providing a sample tube having a pellet at a bottom of the sample tube and a supernatant liquid above the pellet, visually inspecting the sample tube to determine one or more geometric properties of the pellet, and determining an expected height of a top surface of the pellet based on the one or more geometric properties determined in the visual inspection step. The method also includes inserting an aspirator into the supernatant liquid, moving the aspirator downwards towards the expected height of the top surface of the pellet, and aspirating the supernatant liquid through the aspirator.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 15, 2015
    Assignee: Qiagen Gaithersburg, Inc.
    Inventors: Bradley Scott Thomas, Edward Medri, Carl Theodore Edens, Brian Austin Self
  • Patent number: 9212125
    Abstract: The invention relates to a process for the preparation of travoprost of formula (I), comprising that, the compound of formula (II), is stereoselectively reduced, the resulting compound of formula (III), is if desired crystallized, the lactone group of the compound of formula (III) is reduced, the p-phenyl-benzoyl protecting group of the thus obtained compound of formula (IV), is removed, the resulting triol of formula (V), is, if desired after crystallization, transformed by Wittig reaction into the acid of formula (VI), which is then esterified.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: December 15, 2015
    Assignee: CHINOIN GYÓGYSZER ÉS VEGYÉSZETI TERMÉKEK GYÁRA ZRT.
    Inventors: Zsuzsanna Kardos, Tibor Kiss, István Lászlofi, Irén Hortobágyi, Zoltán Bischof, Ádám Bódis, Gábor Havasi
  • Publication number: 20140343299
    Abstract: The invention relates to a process for the preparation of travoprost of formula (I), comprising that, the compound of formula (II), is stereo selectively reduced, the resulting compound of formula (III), is if desired crystallized, the lactone group of the compound of formula (III) is reduced, the p-phenyl-benzoyl protecting group of the thus obtained compound of formula (IV), is removed, the resulting triol of formula (V), is, if desired after crystallization, transformed by Wittig reaction into the acid of formula (VI), which is then esterified.
    Type: Application
    Filed: December 10, 2012
    Publication date: November 20, 2014
    Inventors: Zsuzsanna Kardos, Tibor Kiss, István Lászlofi, Irén Hortobágyi, Zoltán Bischof, Ádám Bódis, Gábor Havasi
  • Patent number: 8389748
    Abstract: Disclosed is a method for preparing a prostaglandin derivative of formula (A): which comprises reacting an aldehyde represented by formula (1): with a 2-oxoalkyl phosphonate in a reaction solvent under the presence of alkali hydroxide as sole base. By carrying out the reaction using an alkali hydroxide as sole base in the reaction system, the desired prostaglandin derivative can be obtained by simple procedures and with high yield.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: March 5, 2013
    Assignees: Sucampo AG, R-Tech Ueno, Ltd.
    Inventors: Ryu Hirata, Tatsuya Matsukawa, Kazuhiro Masuzaki, Ryuji Ueno
  • Patent number: 7776896
    Abstract: This invention is directed to compounds of formula (I): where A, B, D, E, m, and R1-R5 are as described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, clathrates, or prodrugs thereof, which compounds are useful in treating respiratory diseases associated with influenza A viruses, such as for example H5N1 and its mutations. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: August 17, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: William Guilford, Werner Skuballa, Daryl H. Faulds, Monica Kochanny, Wheeseong Lee, Bernd Radüchel
  • Publication number: 20080242714
    Abstract: This invention is directed to compounds of formula (I): where A, B, D, E, m, and R1-R5 are as described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, clathrates, or prodrugs thereof, which compounds are useful in treating respiratory diseases associated with influenza A viruses, such as for example H5N1 and its mutations. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.
    Type: Application
    Filed: March 27, 2008
    Publication date: October 2, 2008
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: William Guilford, Werner Skuballa, Daryl H. Faulds, Monica Kochanny, Wheeseong Lee, Bernd Raduchel
  • Patent number: 7157590
    Abstract: The present invention provides a new and effective process for the synthesis of 17-phenyl-18,19,20-trinor-PGF2? and its derivatives, including the anti-glaucoma drugs Bimatoprost and Latanoprost. The benefit of the present invention rises inter alia from the fact that a major intermediate involved in the synthesis of the above compounds may be isolated from a mixture containing also an undesired isomer, by crystallization. In addition, the undesired isomer may be oxidized to give the starting compound, which is then recycled.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: January 2, 2007
    Assignee: Finetech Laboratories Ltd.
    Inventors: Arie Gutman, Gennady Nisnevich, Marina Etinger, Igor Zaltzman, Lev Yudovitch, Boris Pertsikov
  • Patent number: 6927300
    Abstract: Disclosed is a process for the preparation of the anti-glaucoma drug Latanoprost, in good yield, in large amounts and with desired purity. Also disclosed are novel intermediates for the above process.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: August 9, 2005
    Assignee: FineTech Laboratories LTD
    Inventors: Arie Gutman, Gennadiy Nisnevich, Marina Etinger, Igor Zaltzman, Lev Judovich, Boris Pertsikov
  • Patent number: 6720438
    Abstract: Disclosed is a process for the preparation of the anti-glaucoma drug Latanoprost, in good yield, in large amounts and with desired purity. Also disclosed are novel intermediates for the above process.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: April 13, 2004
    Assignee: FineTech Laboratories Ltd.
    Inventors: Arie Gutman, Gennadiy Nisnevich, Marina Etinger, Igor Zaltzman, Lev Judovich, Boris Pertsikov
  • Publication number: 20040049057
    Abstract: This invention relates to dihydro-furan-2-one derivatives, their intermediates and methods of manufacture.
    Type: Application
    Filed: May 7, 2003
    Publication date: March 11, 2004
    Applicant: Pfizer Inc.
    Inventors: Frank J. Urban, V. John Jasys, Zhengong B. Li
  • Patent number: 6433004
    Abstract: The present invention relates to novel substituted &bgr;,&ggr;-fused lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: August 13, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Patent number: 6268514
    Abstract: The use of nitroethane derivatives of the formula I where: R1 is hydrogen, unsubstituted or substituted C1-C6-alkyl, C3-C6-alkenyl, C3-C6-alkynyl, halogen, cyano or thiocyanato; R2 is hydrogen, formyl; halogen- or C1-C3-alkoxy-substituted or unsubstituted C1-C6-alkylcarbonyl, C2-C6-alkenylcarbonyl, C4-C6-alkyldienylcarbonyl or C2-C6-alkynylcarbonyl; A is unsubstituted or substituted phenyl, naphthyl, quinolyl, quinazolyl, quinoxalyl, 1-methylindolyl, 1-methylbenzimidazolyl, 2-methylindazolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl, pyranyl or thiopyranyl; as microbicides is described.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: July 31, 2001
    Assignee: BASF Aktiengesellschaft
    Inventors: Gerhard Hamprecht, John-Bryan Speakman, Gisela Lorenz, Kurt Eger, Mathias Schmidt, Uta Witt
  • Patent number: 5585501
    Abstract: A method for reduction of an allyl alcohol-type compound, specific to its allylic hydroxyl group, being carried out without any side reactions such as reduction of other portions of the compound or allylic rearrangement, which comprises treating the compound with trialkylsilane in the presence of AlX.sub.3, wherein X refers to a halogen atom.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: December 17, 1996
    Assignee: Shionogi & Co., Ltd.
    Inventors: Mitsuaki Ohtani, Takaharu Matsuura, Yoshinori Hamada, Isamu Yamada, Teruo Sakata, Kimio Takahashi, Morio Kishi
  • Patent number: 5374745
    Abstract: The invention relates to a process for the production of prostaglandin precursors of formula I ##STR1## as well as their enantiomers in which X is A--W or W--A,A is a --C.tbd.C-- group,W is a hydroxymethylene group, in which the OH group can be functionally modified by etherification or esterification,D is a straight-chain or branched-chain alkylene group with 2-5 C atoms each or a ##STR2## group, n i s 1 to 3,E is a --C.tbd.C-- group or a --CR.sub.3 .dbd.CR.sub.4 group with R.sub.3 and R.sub.4 each meaning a hydrogen atom or a C.sub.1 -C.sub.4 alkyl group,R.sub.1 is a hydrogen atom or a hydroxy group, which can be functionally modified as in W,R.sub.2 is a straight-chain or branched-chain alkyl group with 1-7 C atoms, characterized in that vinyl bromides of formula II ##STR3## in which Z means the group ##STR4## and R.sub.1, W, D, E and R.sub.2 have the above-indicated meanings and hydroxy groups unprotected in R.sub.1 and W or represented by an optionally substituted benzoyl radical, a C.sub.1 -C.sub.
    Type: Grant
    Filed: September 29, 1992
    Date of Patent: December 20, 1994
    Assignee: Schering Aktiengesellschaft
    Inventor: Ulrich Klar
  • Patent number: 5219743
    Abstract: The primary hydroxy group of Corey lactone diols is optically selectively acylated to obtain the desired optically active ester and/or diol. The mixture of Corey lactone diols of formulae (Ia) and (Ib): ##STR1## is reacted with an acylating agent optically selectively in the presence of an enzyme and/or a microorganism thereby to acylate, isolate and purify the primary alcohol.
    Type: Grant
    Filed: February 18, 1992
    Date of Patent: June 15, 1993
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Seiichi Takano, Tsutomu Sugahara
  • Patent number: 5079371
    Abstract: The present invention is a process for the production of a ketolactone of formula III ##STR1## which comprises contacting an aldehyde lactone of formula I ##STR2## with a .beta.-ketophosphonate (X.sub.1 --O--).sub.2 --PO--CH.sub.2 --CO--X.sub.15 (II). The ketolactone (III) is a useful intermediate in the synthesis of prostaglandins.
    Type: Grant
    Filed: March 1, 1990
    Date of Patent: January 7, 1992
    Assignee: Upjohn Company
    Inventors: John C. Saddler, John H. Symonds
  • Patent number: 4707555
    Abstract: New optically active intermediates and processes thereto are provided for use in synthesizing therapeutically active prostaglandins of the formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; from a compound of the formula: ##STR2## wherein R.sup.1 is as above and R.sup.2 is hydrogen or a carboxy blocking group convertible to an acid by hydrolysis.
    Type: Grant
    Filed: July 12, 1985
    Date of Patent: November 17, 1987
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David L. Coffen, George W. Holland, W. Harry Mandeville, Perry Rosen, Frederick Wong
  • Patent number: 4650881
    Abstract: Arenes, such as benzoic acid and substituted benzoic acids, are readily thallated by thallium(III) compounds such as the trifluoroacetate and subsequently reacted with palladium chloride and simple olefins, dienes, allylic halides, vinyl halides, vinyl esters, or unsaturated cyclopropanes or unsaturated cyclobutanes to give isocoumarins.
    Type: Grant
    Filed: April 1, 1985
    Date of Patent: March 17, 1987
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Richard C. Larock, Sudarsanan Varaprath
  • Patent number: 4650883
    Abstract: The prostacyclins 7-fluoro-6,9-epoxy-16-substituted-15-hydroxyprost-[4 or 5,13]-dienoic acids and esters useful as anti-secretory agents, blood pressure lowering agents, anti-ulcerogenic agents, anti-hypertensive agents, bronchodilation agents and for combating gastro-hyperacidity and as anti-blood platelet aggregating agents.
    Type: Grant
    Filed: September 9, 1985
    Date of Patent: March 17, 1987
    Assignee: Hoffmann-La Roche Inc.
    Inventors: George W. Holland, Perry Rosen, Hans Maag
  • Patent number: 4558140
    Abstract: New optically active intermediates and processes thereto are provided for use in synthesizing therapeutically active prostaglandins of the formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; from a compound of the formula: ##STR2## wherein R.sup.1 is as above and R.sup.2 is hydrogen or a carboxy blocking group convertible to an acid by hydrolysis.
    Type: Grant
    Filed: March 6, 1984
    Date of Patent: December 10, 1985
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David L. Coffen, George W. Holland, Perry Rosen, Frederick Wong
  • Patent number: 4410710
    Abstract: Naturally occurring iridoids provide the starting material for a unique synthesis sequence to produce prostaglandin intermediates. The iridoid lactone is hydrogenated, converted to an acetal, and rings opened to introduce the carbonyl octenyl side chain in six steps. The intermediate can be converted to prostaglandin as previously demonstrated.
    Type: Grant
    Filed: September 25, 1981
    Date of Patent: October 18, 1983
    Assignee: Research Foundation of the City University of New York
    Inventors: William F. Berkowitz, Satish C. Choudhry, Joseph A. Hrabie